

***In silico* investigation of coding variants potentially affecting the functioning of the glutamatergic N-methyl-D-aspartate receptor in schizophrenia**

Antonia Tsavou^{1,2}, David Curtis^{2,3*}

1. University of Patras, GR 26500, Patras, Greece.
2. UCL Genetics Institute, UCL, Darwin Building, Gower Street, London WC1E 6BT, UK.
3. Centre for Psychiatry, Barts and the London School of Medicine and Dentistry, Charterhouse Square, London EC1M 6BQ, UK.

*Corresponding author: d.curtis@ucl.ac.uk

Abstract

Background

Several lines of evidence support the hypothesis that impaired function of the glutamatergic N-methyl-D-aspartate receptor (NMDAR) might be involved in the aetiology of schizophrenia. NMDAR is activated by phosphorylation by Fyn and there is also some evidence to suggest that abnormalities in Fyn functionality could also be involved in susceptibility to schizophrenia. In a recent weighted burden analysis of exome sequenced schizophrenia cases and controls we noted modest statistical evidence for an enrichment of rare, functional variants in *FYN*, *GRIN1* and *GRIN2B* in schizophrenia cases.

Aims

To test the plausibility of the hypothesis that schizophrenia susceptibility might be associated with genetic variants predicted to cause impaired functioning of NMDAR, either directly or indirectly through impairment of the kinases which phosphorylate it.

Method

In an exome sequenced sample of 4225 schizophrenia cases and 5834 controls rare variants occurring in genes for the NMDAR subunits and for the kinases acting on it were annotated. The counts of disruptive and damaging variants were compared between cases and controls and the distribution of amino acids affected by damaging variants were visualised in ProteinPaint and the RCSB Protein Data Bank. Special attention was paid to tyrosine residues subject to phosphorylation.

Results

There was no suggestion that abnormalities of the serine-threonine kinases or of Src were associated with schizophrenia. 3 cases and no controls had a disruptive variant in *GRIN2A* and 2 cases and no controls had a disruptive variant in *FYN*. 14 cases and 3 controls had damaging variants in *FYN* and all the variants in controls affected amino acid residues in the N-terminal region outside of any known functional domains. By contrast, 10 variants in cases affected amino acids in functional domains and in the 3D structure of Fyn two of the amino acid substitutions, A376T and Q517E, were adjacent to each other. 8 cases and 1 control had damaging variants in *GRIN1* but there was no obvious pattern with respect to particular functional domains being affected in this or other genes. A single case had a variant in *GRIN2A* affecting a well-supported phosphorylation site, Y943C, and three cases had a variant in *FYN* which produce an amino acid change, T216S, which lies two residues away from two adjacent well-supported phosphorylation sites. Aside from this, there was no suggestion that tyrosine phosphorylation sites in Fyn or NMDAR were affected.

Conclusions

The numbers of variants involved are too small for firm conclusions to be drawn. The results are consistent with the hypothesis that about 0.5% of subjects with schizophrenia have disruptive or damaging genetic variants which could plausibly impair functioning of NMDAR directly or indirectly through impairing Fyn function.

Declaration of interest

The authors declare they have no conflict of interest.

Keywords

Schizophrenia; NMDAR; GRIN1; GRIN2A; GRIN2B; FYN.

Introduction

Outside of the cerebellum, the glutamatergic N-methyl-D-aspartate receptor (NMDAR) consists of a tetramer of two NR1 subunits, coded for by the gene *GRIN1*, and two NR2 units, either NR2A or NR2B, coded for by *GRIN2A* and *GRIN2B* (Chen and Roche, 2007). Variants in these genes can lead to with epilepsy, intellectual disability and other neuropsychiatric disorders (XiangWei, Jiang and Yuan, 2018). As recently reviewed, there is evidence from a variety of sources to support the hypothesis that hypofunction of NMDAR may contribute to the pathophysiology of schizophrenia (Balu, 2016). Phencyclidine, which is an NMDAR channel blocker, induces a psychotomimetic state that closely resembles schizophrenia and can produce not only positive symptoms of hallucinations and delusions but also formal thought disorder and negative symptoms (Javitt and Zukin, 1991). Some studies have found reduced levels of *GRIN1* mRNA and/or NRI protein in different brain regions of subjects with schizophrenia (Gao *et al.*, 2000; Law and Deakin, 2001; Stan *et al.*, 2015; Catts *et al.*, 2016). Patients with autoimmune NMDAR encephalitis can present with psychotic symptoms, memory deficits and catatonic symptoms (Dalmau *et al.*, 2011) and patients with an initial diagnosis of schizophrenia are reported to have increased rates of NMDAR antibodies (Steiner *et al.*, 2013). *GRIN2A* was included in one of the 108 implicated regions in a large genome-wide association study of schizophrenia (Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014) and the set of genes coding for proteins associated with NMDAR was found to be enriched for both *de novo* copy number variants (CNVs) and small *de novo* mutations (Kirov *et al.*, 2012; Fromer *et al.*, 2014). In the Swedish schizophrenia study including nearly 5000 exome-sequenced schizophrenia cases there was an enrichment of ultra-rare, singleton variants predicted to be gene-disruptive among the set of genes encoding interactors with NMDAR (Genovese *et al.*, 2016). Overall, there are contributions to the genetic risk of schizophrenia from common variants, CNVs and rare coding variants (Coelewij and Curtis, 2018) and it is quite possible that these might include variants within genes encoding for NMDAR.

A fundamental mechanism for regulating NMDAR function is by phosphorylation, which affects both the trafficking of the receptor and its channel properties, as has been reviewed in detail elsewhere (Chen and Roche, 2007). The subunits contain many serine/threonine phosphorylation sites which are substrates for protein kinases A, B and C (PKA, PKB and PKC), calcium/calmodulin-dependent protein kinase II (CaMKII) and casein kinase II (CKII). Phosphorylation of these sites can have a variety of effects on the pharmacological functioning of NMDAR. Separately, the subunits also contain tyrosine residues which are substrates for phosphorylation by protein tyrosine kinases, in particular Fyn and Src, and this can affect NMDAR function as well as trafficking and endocytosis so that tyrosine phosphorylation by these kinases serves to upregulate NMDAR (Ali and Salter, 2001). The Tyr 1325 residue of NR2A is most prominently phosphorylated *in vitro* by Fyn and mice engineered to have a homozygous Tyr-1325-Phe mutation to prevent the phosphorylation of this site are reported to show some antidepressant-like behaviour (Taniguchi *et al.*, 2009). Fyn deficient mice show an increased acoustic startle response under bright light and this is accompanied by increased serotonergic and dopaminergic activity in the prefrontal cortex and limbic system (Hironaka, Yagi and Niki, 2002). Haloperidol injection activates Fyn in mice and increases NR2B phosphorylation while Fyn deficient mice are resistant to haloperidol-induced catalepsy (Hattori *et al.*, 2006). Alternative mRNA splicing with lower levels of Fyn protein has been reported to occur in schizophrenia cases and their relatives (Hattori *et al.*, 2009) and in a recent GWAS of schizophrenia rs7757969, which lies in an intron of *FYN*, the gene which codes for Fyn, was significant at $p = 4.8 \times 10^{-8}$ (Li *et al.*, 2017). Of note, Fyn itself is subject to phosphorylation and is activated by autophosphorylation of a

conserved residue, tyrosine 416 (Y416), a process which is subject to dopaminergic and cholinergic regulation (Mao and Wang, 2015).

We carried out an analysis of the exome-sequenced Swedish schizophrenia cases and controls but in contrast to the previously reported study (Genovese *et al.*, 2016) we did not restrict attention to only singleton variants predicted to completely disrupt gene-functioning but included all rare variants, though with a weighting scheme to give higher weight to variants predicted to have a more deleterious effect (Curtis *et al.*, 2018). For this weighted burden analysis the strength of evidence implicating each gene is summarised as the signed log p value (SLP) and we noted that the set of genes with most evidence for an excess of rare, damaging variants in schizophrenia cases was the set denoted "FMRP targets" (gene set SLP = 7.1) and that within this set the most strongly implicated gene was *FYN*, with SLP = 3.4. Other genes within this set included *GRIN1* (SLP = 1.7) and *GRIN2B* (SLP = 2.1).

These results suggested to us the possibility that genetic variants might increase susceptibility to schizophrenia by impairing the normal functioning of NMDAR through different mechanisms. This might be through variants within the genes coding for the NMDAR subunits or through variants in genes such as *FYN* whose products would normally upregulate NMDAR. Such variants might completely disrupt the functioning of the gene, by producing stop codons, frameshifts or splice site changes. Alternatively they might introduce amino acid changes which critically affected the functioning of the protein. In particular, a coding variant changing a tyrosine residue which was a target of Fyn might have a similar effect to a deleterious variant in *FYN* itself. Accordingly we decided to investigate more closely the coding variants occurring in genes for the NMDAR subunits and the kinases acting on them.

Methods

We used the same dataset as had been used in the previously reported ultra-rare variant and weighted burden analyses (Genovese *et al.*, 2016; Curtis *et al.*, 2018), consisting of exome-sequenced Swedish subjects of whom there were 4225 schizophrenia cases and 5834 controls. We restricted attention to the 23 genes which code for the subunits of the NMDAR protein and the kinases which are involved in its phosphorylation, as listed in Table 1. Variants were annotated with using VEP, PolyPhen and SIFT (Kumar, Henikoff and Ng, 2009; Adzhubei, Jordan and Sunyaev, 2013; McLaren *et al.*, 2016). We restricted attention to variants which were both rare, occurring in a total of no more than 10 subjects (minor allele frequency (MAF) < 0.00005), and predicted either to completely disrupt gene functioning (frameshift, stop-gained and essential splice site variants) or to be potentially damaging. Potentially damaging variants were defined as being non-synonymous variants either predicted to be deleterious by SIFT or to be possibly/probably damaging by PolyPhen (or both). Population frequencies for all variants studied were obtained from gnomAD (Lek *et al.*, 2016). For the damaging variants, we visualised the distribution of the altered amino acid residues across functional domains of the protein using the ProteinPaint web application provided at <https://pecan.stjude.cloud/home> (Zhou *et al.*, 2016). In order to assess whether damaging variants might disrupt phosphorylation sites we used the information provided by PhosphoSitePlus (Hornbeck *et al.*, 2015). For each protein, this provides information regarding which residues are subject to phosphorylation and other modifications along with the number of references which support this modification from high-throughput and low-throughput experiments, the latter being more reliable. For the assessment of the possible impact of variants on phosphorylation sites we restricted attention to tyrosine residues in the NMDAR subunits and Fyn. In order to visualise the distribution of altered amino acid

residues in the 3D structure of the protein we obtained structures from the RCSB Protein Data Bank at www.rcsb.org (Berman *et al.*, 2000) and colour-coded altered residues using the JSmol viewer provided there. Since the preliminary results did not suggest that disturbance of serine-threonine kinase functioning was associated with schizophrenia, for the 3D studies we restricted investigation to NMDAR, Fyn and Src.

Results

Table 2 shows the summary results for the genes involved as obtained from the original weighted burden analysis. This shows that *GRIN1*, *GRIN2B* and *FYN* have modestly positive SLP values although as previously stated none of the individual gene results are formally statistically significant. In this analysis, three disruptive mutations had been assigned to *GRIN2B*. However on further examination of the downloaded VCF file it transpired these were all in the same subject and reflected a single frameshift mutation which produced a sequence change that had been annotated as three separate frameshift mutations close to each other. Once this was corrected there was one case and one control with a disruptive variant in *GRIN2B* and no excess of damaging variants in cases. 2 cases and no controls had a disruptive variant in *FYN* and both *GRIN1* and *FYN* had an excess of damaging variants in cases. Of note, although *GRIN2A* produced only a very small SLP in the weighted burden analysis (0.14), three cases and no controls had a disruptive variant in this gene. By contrast, *SRC* had an excess of damaging variants in controls and overall there was no suggestion that there was an excess of rare disruptive and damaging variants in cases in the genes coding for the serine-threonine kinases. Table 3 shows a detailed breakdown of the genotypes and amino acid changes in *GRIN1*, *GRIN2A*, *GRIN2B* and *FYN*. The variant frequencies from gnomAD are shown for Finnish and Non-Finnish Europeans and all variants were rare (MAF=0.001 or less) in all other populations except for the variant in *FYN* at 6:112041068, which has MAF=0.002 in African Americans.

As shown in Figure 1 and Supplementary Figure 1, for almost all genes the distribution of damaging variants across protein domains did not reveal any particular patterns and there was no marked tendency for a specific functional domain to be enriched for damaging variants in cases. NR1 has an excess of damaging variants in cases and these are widely distributed. The only gene to show a pattern in the distribution of damaging variants was Fyn. As shown in Figure 1d and Supplementary Figure 1d, the three amino acid residues altered in controls all occurred in the N-terminal region of the protein to which no functional domain is assigned. By contrast, ten cases had a genetic variant which would alter an amino acid residue in one of the functional domains.

With regard to phosphorylation sites, experimental support for each site can be quantified by the number of supporting references (high throughput / low throughput). The best supported site in NR2A is Y943 (134/2) and one case has a Y943C variant. In NR2B three cases and two controls have Y1371C but this site has only modest support (11/1). One control has a Y30C substitution in Fyn but this site has only low support (0/1). No other well supported sites were directly affected. However it may be worth noting that there two well supported sites adjacent to each other in Fyn, Y213 (1800/1) and Y214 (671/1), and that three cases have a T216S substitution. It is not inconceivable that this change two residues away might be sufficient to disrupt recognition of the site and hence impair phosphorylation.

In general, examination of the 3D localisation of the substitutions did not yield any new insights. However using model 2DQ7 (Kinoshita *et al.*, 2006) for Fyn did reveal that A376T

(observed in two cases) and Q517E (observed in one case) end up adjacent to each other in the folded protein. This is illustrated in Supplementary Figure 2.

On examining the distribution of variants across subjects in *GRIN1*, *GRIN2A*, *GRIN2B* and *FYN*, it emerged that one case had a damaging variant in *GRIN1* and a frameshift variant in *GRIN2A* while another subject had a damaging variant in *GRIN1* and in *GRIN2B*. No other subject had more than one variant in these genes.

Discussion

The number of variants involved is too small for any definite conclusions to be reached. However there are a few points of interest. Firstly, there is no evidence to implicate disruption of serine-threonine phosphorylation or disruption of tyrosine phosphorylation by Src. Thus, if impaired tyrosine phosphorylation of NMDAR has any relevance to schizophrenia aetiology this seems likely to be specific to Fyn rather than Src. It is also not the case that amino acid substitutions in NMDAR preventing phosphorylation occur commonly in schizophrenia - we observe this in only a single case out of 4225. Nor is there strong evidence that variants interfering with Fyn autophosphorylation occur commonly. We see no definite examples of this and the closest we come to any support for this is the observation that three cases have an amino acid substitution two residues away from a tyrosine residue which is well supported as a phosphorylation site. We do observe that 3 cases and no controls have disrupting variants in *GRIN2A* and that 8 cases and 1 control have damaging variants in *GRIN1*. 14 cases and 3 controls have damaging variants in *FYN* but if we restrict attention to functional domains of the protein this applies to 10 cases and no control. Aside from that, we cannot discern any obvious pattern to the distribution of damaging variants. Overall, these possibly relevant variants were seen in about 0.5% of the cases.

These results are perfectly consistent with the hypothesis that the risk of schizophrenia may be increased by genetic variants impairing NMDAR functioning either directly or by reducing phosphorylation by Fyn. However this study provides at best only modest further support. It is hoped that the situation may become clearer as larger numbers of cases are sequenced. It might also be helpful to carry out functional studies to determine the effect of these variants *in vitro* and *in vivo*. This approach demonstrates ways in which additional information of possible biological relevance can be mined from sequencing studies.

Acknowledgment

AT was supported by the Erasmus+ Mobility for Traineeships programme.

References

- Adzhubei, I., Jordan, D. M. and Sunyaev, S. R. (2013) 'Predicting functional effect of human missense mutations using PolyPhen-2.', *Current protocols in human genetics*. NIH Public Access, 7 Unit7.20. doi: 10.1002/0471142905.hg0720s76.
- Ali, D. W. and Salter, M. W. (2001) 'NMDA receptor regulation by Src kinase signalling in excitatory synaptic transmission and plasticity.', *Current opinion in neurobiology*, 11(3), pp. 336–42.
- Balu, D. T. (2016) 'The NMDA Receptor and Schizophrenia: From Pathophysiology to Treatment.', *Advances in pharmacology (San Diego, Calif.)*. NIH Public Access, 76, pp. 351–82. doi: 10.1016/bs.apha.2016.01.006.
- Berman, H. M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T. N., Weissig, H., Shindyalov, I. N. and Bourne, P. E. (2000) 'The Protein Data Bank.', *Nucleic acids research*, 28(1), pp. 235–42.
- Catts, V. S., Lai, Y. L., Weickert, C. S., Weickert, T. W. and Catts, S. V. (2016) 'A quantitative review of the postmortem evidence for decreased cortical N-methyl-d-aspartate receptor expression levels in schizophrenia: How can we link molecular abnormalities to mismatch negativity deficits?', *Biological Psychology*, 116, pp. 57–67. doi: 10.1016/j.biopsycho.2015.10.013.
- Chen, B.-S. and Roche, K. W. (2007) 'Regulation of NMDA receptors by phosphorylation.', *Neuropharmacology*. NIH Public Access, 53(3), pp. 362–8. doi: 10.1016/j.neuropharm.2007.05.018.
- Coelewij, L. and Curtis, D. (2018) 'Mini-review: Update on the genetics of schizophrenia', *Annals of Human Genetics*. Wiley/Blackwell (10.1111), 82(5), pp. 239–243. doi: 10.1111/ahg.12259.
- Curtis, D., Coelewij, L., Liu, S.-H., Humphrey, J. and Mott, R. (2018) 'Weighted Burden Analysis of Exome-Sequenced Case-Control Sample Implicates Synaptic Genes in Schizophrenia Aetiology', *Behavior Genetics*. Cold Spring Harbor Laboratory, p. 203521. doi: 10.1007/s10519-018-9893-3.
- Dalmau, J., Lancaster, E., Martinez-Hernandez, E., Rosenfeld, M. R. and Balice-Gordon, R. (2011) 'Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis.', *The Lancet. Neurology*. NIH Public Access, 10(1), pp. 63–74. doi: 10.1016/S1474-4422(10)70253-2.
- Fromer, M., Pocklington, A. J., Kavanagh, D. H., Williams, H. J., Dwyer, S., Gormley, P., Georgieva, L., Rees, E., Palta, P., Ruderfer, D. M., Carrera, N., Humphreys, I., Johnson, J. S., Roussos, P., Barker, D. D., Banks, E., Milanova, V., Grant, S. G., Hannon, E., Rose, S. A., Chambert, K., Mahajan, M., Scolnick, E. M., Moran, J. L., Kirov, G., Palotie, A., McCarroll, S. A., Holmans, P., Sklar, P., Owen, M. J., Purcell, S. M. and O'Donovan, M. C. (2014) 'De novo mutations in schizophrenia implicate synaptic networks', *Nature*, 506(7487), pp. 179–184. doi: 10.1038/nature12929.
- Gao, X.-M., Sakai, K., Roberts, R. C., Conley, R. R., Dean, B. and Tamminga, C. A. (2000) 'Ionotropic Glutamate Receptors and Expression of N-Methyl- d -Aspartate Receptor Subunits in Subregions of Human Hippocampus: Effects of Schizophrenia', *American Journal of Psychiatry*, 157(7), pp. 1141–1149. doi: 10.1176/appi.ajp.157.7.1141.
- Genovese, G., Fromer, M., Stahl, E. A., Ruderfer, D. M., Chambert, K., Landén, M., Moran, J. L., Purcell, S. M., Sklar, P., Sullivan, P. F., Hultman, C. M. and McCarroll, S. A. (2016) 'Increased burden of ultra-rare protein-altering variants among 4,877 individuals with schizophrenia', *Nature Neuroscience*, 19(11), pp. 1433–1441. doi: 10.1038/nn.4402.

Hattori, K., Fukuzako, H., Hashiguchi, T., Hamada, S., Murata, Y., Isosaka, T., Yuasa, S. and Yagi, T. (2009) 'Decreased expression of Fyn protein and disbalanced alternative splicing patterns in platelets from patients with schizophrenia.', *Psychiatry research*, 168(2), pp. 119–28. doi: 10.1016/j.psychres.2008.04.014.

Hattori, K., Uchino, S., Isosaka, T., Maekawa, M., Iyo, M., Sato, T., Kohsaka, S., Yagi, T. and Yuasa, S. (2006) 'Fyn is required for haloperidol-induced catalepsy in mice.', *The Journal of biological chemistry*. American Society for Biochemistry and Molecular Biology, 281(11), pp. 7129–35. doi: 10.1074/jbc.M511608200.

Hironaka, N., Yagi, T. and Niki, H. (2002) 'Light-potentiation of acoustic startle response (ASR) and monoamine efflux related to fearfulness in Fyn-deficient mice.', *Brain research. Molecular brain research*, 98(1–2), pp. 102–10.

Hornbeck, P. V., Zhang, B., Murray, B., Kornhauser, J. M., Latham, V. and Skrzypek, E. (2015) 'PhosphoSitePlus, 2014: mutations, PTMs and recalibrations', *Nucleic Acids Research*, 43(D1), pp. D512–D520. doi: 10.1093/nar/gku1267.

Javitt, D. C. and Zukin, S. R. (1991) 'Recent advances in the phencyclidine model of schizophrenia', *American Journal of Psychiatry*, 148(10), pp. 1301–1308. doi: 10.1176/ajp.148.10.1301.

Kinoshita, T., Matsubara, M., Ishiguro, H., Okita, K. and Tada, T. (2006) 'Structure of human Fyn kinase domain complexed with staurosporine.', *Biochemical and biophysical research communications*, 346(3), pp. 840–4. doi: 10.1016/j.bbrc.2006.05.212.

Kirov, G., Pocklington, A. J., Holmans, P., Ivanov, D., Ikeda, M., Ruderfer, D., Moran, J., Chambert, K., Toncheva, D., Georgieva, L., Grozeva, D., Fjodorova, M., Wollerton, R., Rees, E., Nikolov, I., van de Lagemaat, L. N., Bayés, À., Fernandez, E., Olason, P. I., Böttcher, Y., Komiyama, N. H., Collins, M. O., Choudhary, J., Stefansson, K., Stefansson, H., Grant, S. G. N., Purcell, S., Sklar, P., O'Donovan, M. C. and Owen, M. J. (2012) 'De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia', *Molecular Psychiatry*, 17(2), pp. 142–153. doi: 10.1038/mp.2011.154.

Kumar, P., Henikoff, S. and Ng, P. C. (2009) 'Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm', *Nature Protocols*, 4(8), pp. 1073–1081. doi: 10.1038/nprot.2009.86.

Law, A. J. and Deakin, J. F. (2001) 'Asymmetrical reductions of hippocampal NMDAR1 glutamate receptor mRNA in the psychoses.', *Neuroreport*, 12(13), pp. 2971–4.

Lek, M., Karczewski, K. J., Minikel, E. V., Samocha, K. E., Banks, E., Fennell, T., O'Donnell-Luria, A. H., Ware, J. S., Hill, A. J., Cummings, B. B., Tukiainen, T., Birnbaum, D. P., Kosmicki, J. A., Duncan, L. E., Estrada, K., Zhao, F., Zou, J., Pierce-Hoffman, E., Berghout, J., Cooper, D. N., Deflaux, N., DePristo, M., Do, R., Flannick, J., Fromer, M., Gauthier, L., Goldstein, J., Gupta, N., Howrigan, D., Kiezun, A., Kurki, M. I., Moonshine, A. L., Natarajan, P., Orozco, L., Peloso, G. M., Poplin, R., Rivas, M. A., Ruano-Rubio, V., Rose, S. A., Ruderfer, D. M., Shakir, K., Stenson, P. D., Stevens, C., Thomas, B. P., Tiao, G., Tusie-Luna, M. T., Weisburd, B., Won, H.-H., Yu, D., Altshuler, D. M., Ardissino, D., Boehnke, M., Danesh, J., Donnelly, S., Elosua, R., Florez, J. C., Gabriel, S. B., Getz, G., Glatt, S. J., Hultman, C. M., Kathiresan, S., Laakso, M., McCarroll, S., McCarthy, M. I., McGovern, D., McPherson, R., Neale, B. M., Palotie, A., Purcell, S. M., Saleheen, D., Scharf, J. M., Sklar, P., Sullivan, P. F., Tuomilehto, J., Tsuang, M. T., Watkins, H. C., Wilson, J. G., Daly, M. J., MacArthur, D. G., Exome Aggregation Consortium, O'Donnell-Luria, A. H., Ware, J. S., Hill, A. J., Cummings, B. B., Tukiainen, T., Birnbaum, D. P., Kosmicki, J. A., Duncan, L. E., Estrada, K., Zhao, F., Zou, J., Pierce-Hoffman, E., Berghout, J., Cooper, D. N., Deflaux, N., DePristo, M., Do, R., Flannick, J., Fromer, M., Gauthier, L., Goldstein, J., Gupta, N., Howrigan, D., Kiezun, A., Kurki, M. I., Moonshine, A. L., Natarajan, P., Orozco, L., Peloso,

G. M., Poplin, R., Rivas, M. A., Ruano-Rubio, V., Rose, S. A., Ruderfer, D. M., Shakir, K., Stenson, P. D., Stevens, C., Thomas, B. P., Tiao, G., Tusie-Luna, M. T., Weisburd, B., Won, H.-H., Yu, D., Altshuler, D. M., Ardissino, D., Boehnke, M., Danesh, J., Donnelly, S., Elosua, R., Florez, J. C., Gabriel, S. B., Getz, G., Glatt, S. J., Hultman, C. M., Kathiresan, S., Laakso, M., McCarroll, S., McCarthy, M. I., McGovern, D., McPherson, R., Neale, B. M., Palotie, A., Purcell, S. M., Saleheen, D., Scharf, J. M., Sklar, P., Sullivan, P. F., Tuomilehto, J., Tsuang, M. T., Watkins, H. C., Wilson, J. G., Daly, M. J., MacArthur, D. G. and Exome Aggregation Consortium (2016) 'Analysis of protein-coding genetic variation in 60,706 humans', *Nature*. Nature Publishing Group, 536(7616), pp. 285–291. doi: 10.1038/nature19057.

Li, Z., Chen, J., Yu, H., He, L., Xu, Y., Zhang, D., Yi, Q., Li, C., Li, X., Shen, J., Song, Z., Ji, W., Wang, M., Zhou, J., Chen, B., Liu, Y., Wang, J., Wang, P., Yang, P., Wang, Q., Feng, G., Liu, B., Sun, W., Li, B., He, G., Li, W., Wan, C., Xu, Q., Li, W., Wen, Z., Liu, K., Huang, F., Ji, J., Ripke, S., Yue, W., Sullivan, P. F., O'Donovan, M. C. and Shi, Y. (2017) 'Genome-wide association analysis identifies 30 new susceptibility loci for schizophrenia', *Nature Genetics*, 49(11). doi: 10.1038/ng.3973.

Mao, L.-M. and Wang, J. Q. (2015) 'Dopaminergic and cholinergic regulation of Fyn tyrosine kinase phosphorylation in the rat striatum in vivo.', *Neuropharmacology*. NIH Public Access, 99, pp. 491–9. doi: 10.1016/j.neuropharm.2015.08.017.

McLaren, W., Gil, L., Hunt, S. E., Riat, H. S., Ritchie, G. R. S., Thormann, A., Flicek, P. and Cunningham, F. (2016) 'The Ensembl Variant Effect Predictor.', *Genome biology*, 17(1), p. 122. doi: 10.1186/s13059-016-0974-4.

Schizophrenia Working Group of the Psychiatric Genomics Consortium (2014) 'Biological insights from 108 schizophrenia-associated genetic loci', *Nature*, 511, pp. 421–427. doi: 10.1038/nature13595.

Stan, A. D., Ghose, S., Zhao, C., Hulsey, K., Mihalakos, P., Yanagi, M., Morris, S. U., Bartko, J. J., Choi, C. and Tamminga, C. A. (2015) 'Magnetic resonance spectroscopy and tissue protein concentrations together suggest lower glutamate signaling in dentate gyrus in schizophrenia', *Molecular Psychiatry*, 20(4), pp. 433–439. doi: 10.1038/mp.2014.54.

Steiner, J., Walter, M., Glanz, W., Sarnyai, Z., Bernstein, H. G., Vielhaber, S., Kastner, A., Skalej, M., Jordan, W., Schiltz, K., Klingbeil, C., Wandinger, K. P., Bogerts, B. and Stoecker, W. (2013) 'Increased Prevalence of Diverse N -Methyl-D-Aspartate Glutamate Receptor Antibodies in Patients With an Initial Diagnosis of Schizophrenia: Specific Relevance of IgG NR1a Antibodies for Distinction From N -Methyl-D-Aspartate Glutamate Receptor Encephalitis', *JAMA Psychiatry*, 70(3), pp. 271–278. doi: 10.1001/2013.jamapsychiatry.86.

Taniguchi, S., Nakazawa, T., Tanimura, A., Kiyama, Y., Tezuka, T., Watabe, A. M., Katayama, N., Yokoyama, K., Inoue, T., Izumi-Nakaseko, H., Kakuta, S., Sudo, K., Iwakura, Y., Umemori, H., Inoue, T., Murphy, N. P., Hashimoto, K., Kano, M., Manabe, T. and Yamamoto, T. (2009) 'Involvement of NMDAR2A tyrosine phosphorylation in depression-related behaviour.', *The EMBO journal*. European Molecular Biology Organization, 28(23), pp. 3717–29. doi: 10.1038/emboj.2009.300.

XiangWei, W., Jiang, Y. and Yuan, H. (2018) 'De novo mutations and rare variants occurring in NMDA receptors', *Current Opinion in Physiology*, 2, pp. 27–35. doi: 10.1016/j.cophys.2017.12.013.

Zhou, X., Edmonson, M. N., Wilkinson, M. R., Patel, A., Wu, G., Liu, Y., Li, Y., Zhang, Z., Rusch, M. C., Parker, M., Becksfort, J., Downing, J. R. and Zhang, J. (2016) 'Exploring genomic alteration in pediatric cancer using ProteinPaint', *Nature Genetics*. Nature Publishing Group, 48(1), pp. 4–6. doi: 10.1038/ng.3466.

Table 1

Genes for the NMDAR protein and the kinases involved in its phosphorylation.

Protein	Gene(s)
Glutamatergic NMDA receptor (NMDAR)	<i>GRIN1, GRIN2A, GRIN2B</i>
Protein kinase A (PKA)	<i>PRKACA, PRKACB, PRKACG, PRKAR1A, PRKAR1B, PRKAR2A, PRKAR2B</i>
Protein kinase C (PKC)	<i>PRKCA, PRKCB, PRKCG</i>
Protein kinase B (PKB)	<i>PTK2B</i>
Calcium/calmodulin-dependent protein kinase II (CaMKII)	<i>CAMK2A, CAMK2B, CAMK2G, CAMK2D</i>
Casein kinase II (CKII)	<i>CSNK2A1, CSNK2A2, CSNK2B</i>
Proto-oncogene tyrosine-protein kinase Fyn	<i>FYN</i>
Proto-oncogene tyrosine-protein kinase Src	<i>SRC</i>

Table 2

Results obtained from original weighted burden analysis for genes coding for NMDAR and the kinases acting on it. The SLP is the signed log p value, indicating the overall level of support for association with schizophrenia obtained from the weighted burden analysis. For rare variants, occurring in no more than ten subjects, the total counts for gene-disruptive and gene-damaging variants in controls and cases is shown.

Protein	Gene	SLP	Disruptive		Damaging	
			Controls	Cases	Controls	Cases
NMDAR	<i>GRIN1</i>	1.7	0	0	1	8
	<i>GRIN2A</i>	0.14	0	3	25	25
	<i>GRIN2B</i>	2.06	1	1	16	16
Fyn	<i>FYN</i>	3.37	0	2	3	14
Src	<i>SRC</i>	-0.22	0	0	10	5
Protein kinase C	<i>PRKACA</i>	0.13	0	0	0	3
	<i>PRKACB</i>	-0.39	1	0	5	3
	<i>PRKACG</i>	0.34	0	0	5	6
	<i>PRKAR1A</i>	-1.08	0	0	40	19
	<i>PRKAR1B</i>	-1.26	0	0	9	2
	<i>PRKAR2A</i>	-0.06	0	0	18	9
	<i>PRKAR2B</i>	1.16	0	0	9	7
	<i>PRKCA</i>	-0.12	0	0	32	21
Protein kinase C	<i>PRKCB</i>	-0.16	0	0	12	4
	<i>PRKCG</i>	-0.25	0	0	4	1
	<i>PTK2B</i>	-0.84	1	0	24	22
Protein kinase B	<i>CAMK2A</i>	0.63	0	1	1	4
	<i>CAMK2B</i>	0.59	0	0	0	2
	<i>CAMK2G</i>	-0.16	0	0	10	6
	<i>CAMK2D</i>	-0.29	0	0	10	3
Casein kinase II	<i>CSNK2A1</i>	0.27	0	0	2	3
	<i>CSNK2A2</i>	0.35	1	0	0	4
	<i>CSNK2B</i>	-0.46	0	0	2	0

Table 3

Table showing effects of rare disruptive and damaging variants in *GRIN1*, *GRIN2A*, *GRIN2B* and *FYN* along with population allele frequencies obtained from gnomAD.


Gene	Position	DNA change	Amino acid change as called by VEP	Count in controls	Count in cases	Non-Finnish European allele frequency	Finnish allele frequency
GRIN1	9:140034149	Gcc/Acc	A/T	0	1	9.13E-06	4.49E-05
	9:140052907	Gcc/Acc	A/T	1	2	0.000179	0
	9:140052955	Ggc/Cgc	G/R	0	1	8.99E-06	0
	9:140055795	aAg/aTg	K/M	0	1	9.04E-06	0
	9:140057671	tCg/tGg	S/W	0	1	8.99E-06	0
	9:140057749	cCc/cTc	P/L	0	1	8.98E-06	0
	9:140059705	aCc/aTc	T/I	0	1	8.96E-06	0
GRIN2A	16:9857046	cGc/cAc	R/H	0	1	2.69E-05	0
	16:9857305	Cct/Gct	P/A	1	0	8.97E-06	0
	16:9857386	ggGAaa/ggAaa	GK/GX	0	2	2.69E-05	0
	16:9857503	Agg/Ggg	R/G	3	3	0.000188	0
	16:9857517	aTt/aCt	I/T	1	2	7.17E-05	0
	16:9857532	cAt/cCt	H/P	0	1	8.96E-06	0
	16:9857538	cGt/cAt	R/H	1	0	8.96E-06	0
	16:9857823	tTg/tGg	L/W	3	0	0.000206	0
	16:9857833	Cac/Tac	H/Y	1	1	1.79E-05	0
	16:9857974	Gag/Aag	E/K	2	0	1.79E-05	0
	16:9858040	Gat/Tat	D/Y	0	1	8.98E-06	0
	16:9858493	Cgg/Tgg	R/W	1	0	2.69E-05	0
	16:9858511	Caa/Aaa	Q/K	1	0	8.96E-06	0
	16:9858573	tAc/tGc	Y/C	0	1	8.96E-06	0
	16:9858666	tCc/tGc	S/C	0	2	3.58E-05	0
	16:9858690	aTt/aCt	I/T	0	1	8.96E-06	0
	16:9858774	aTt/aCt	I/T	3	1	7.19E-05	4.48E-05
	16:9862746	Tgc/Cgc	C/R	0	1	8.98E-06	0
	16:9862766	cGc/cAc	R/H	1	0	1.80E-05	0
	16:9892242	Atc/Gtc	I/V	0	3	2.69E-05	0
	16:9916247	cGa/cAa	R/Q	1	0	8.96E-06	0
	16:9928037	Gtt/Ctt	V/L	1	0	8.98E-06	0
	16:9934519	Cct/Gct	P/A	0	1	0	0
	16:9934902	aTt/aGt	I/S	0	1	8.97E-06	0
	16:9943670	cCc/cAc	P/H	0	1	4.48E-05	0
	16:9984857	Cgg/Tgg	R/W	0	1	8.96E-06	0
	16:10031933	gGc/gCc	G/A	1	0	2.70E-05	0
	16:10032093	Cgc/Tgc	R/C	0	1	8.99E-06	0
	16:10032122	gAc/gCc	D/A	1	0	8.99E-06	0
	16:10032128	tCc/tTc	S/F	1	0	8.99E-06	0

	16:10032197	tCc/tTc	S/F	2	0	1.80E-05	0
	16:10032276	Ttc/Atc	F/I	0	1	9.00E-05	0
	16:10273938	Cag/Gag	Q/E	0	1	0	0
	16:10274097	Gag/Tag	E/*	0	1	1.81E-05	0
GRIN2B	12:13715832	tGt/tAt	C/Y	0	1	8.95E-06	0
	12:13715850	cGt/cCt	R/P	1	0	8.95E-06	0
	12:13716060	tAc/tGc	Y/C	2	3	7.16E-05	4.48E-05
	12:13716273	cGg/cAg	R/Q	1	0	8.95E-06	0
	12:13716318	cCg/cGg	P/R	0	1	8.95E-06	0
	12:13716424	Aac/Gac	N/D	1	0	8.96E-06	0
	12:13716667	Gga/Aga	G/R	1	0	1.80E-05	0
	12:13716940	Gcc/Tcc	A/S	1	1	1.79E-05	0
	12:13716970	Gtc/Atc	V/I	1	0	1.79E-05	0
	12:13716998	tcc/tcAACcC	S/STX	0	1	8.95E-06	0
	12:13717001	aGc/aTc	S/I	1	0	8.95E-06	0
	12:13717004	gaC/gaA	D/E	0	1	8.95E-06	0
	12:13717035	Ggc/Agc	G/S	0	1	0.000269	0
	12:13717061	cTg/cCg	L/P	1	0	8.95E-06	0
	12:13717096	aGg/aAg	R/K	2	6	0.000134	0
	12:13717104	Agc/Ggc	S/G	1	0	9.14E-06	0
	12:13717125	Gaa/Aaa	E/K	0	1	8.97E-06	0
	12:13717564	Gtc/Ttc	V/F	1	0	8.96E-06	0
	12:13720189	tgT/tgA	C/*	1	0	0	0
	12:13764713	Ctt/Att	L/I	0	1	1.81E-05	0
	12:13768544	gAt/gTt	D/V	1	0	9.03E-06	0
	12:13828708	aTc/aCc	I/T	1	0	0	0
	12:13828743	Cag/Gag	Q/E	0	1	9.85E-05	0
	12:13906758	Gca/Aca	A/T	0	2	6.27E-05	0
FYN	6:111983007	Tta/Ata	L/I	0	2	1.79E-05	0
	6:112015725	caG/ca	Q/X	0	1	8.95E-06	0
	6:112015890	aCc/aGc	T/S	0	3	2.69E-05	0
	6:112021352	caG/ca	Q/X	0	1	8.98E-06	0
	6:112024138	cGc/cAc	R/H	0	1	2.69E-05	0
	6:112025201	T/C	Splice donor variant	0	1	8.97E-06	0
	6:112029200	Cgt/Tgt	R/C	1	0	1.80E-05	4.49E-05
	6:112029218	Gtc/Atc	V/I	1	2	0.00034	0
	6:112041026	tAt/tGt	Y/C	1	0	8.96E-06	0


Figure 1

Variants from each gene in the relevant transcript as displayed by *ProteinPaint*. Variants seen in cases are coloured black while variants seen in controls are coloured grey. Where more than one case or one control has the same variant the number possessing it is shown within the circle and the size of the circle is increased proportionately.


(a) *GRIN1* variants affecting NR1



(b) *GRIN2A* variants affecting NR2A



(c) *GRIN2B* variants affecting NR2B



(d) *FYN* variants affecting Fyn

